Radiopharmaceutical system manufacturer Cyclopharm has entered into an agreement to supply the Veterans Health Administration (VA), the largest US government health care system, with the pharmaceutical and consumable components of its Technegas imaging system. The Interim Agreement immediately provides the 120 Veterans Affairs hospitals, which have nuclear medicine departments, access to an agreed contract for…
Cyclopharm’s Technegas radiopharmaceutical imaging system has achieved a streamlined reimbursement approval process in the United States, boosting its prospects in what is the world’s largest market. The Sydney company has received a Coding Determination for Technegas from the Center for Medicare Medicaid Services (CMS), which means users will have a unique identifier which streamlines their…
Radiopharmaceutical manufacturer Cyclopharm has announced unaudited FY23 revenue up 14 percent to $28.9 million and increasing momentum in the roll out of its Technegas lung imaging technology in the United States. The US launch has resulted in 80 issued contracts to date, covering more than 280 individual institutions, of which six are at the final…
Radiopharmaceutical manufacturer Cyclopharm has announced that Duke University Hospital in the United States has signed the first commercial contract for the use of its Technegas lung imaging system in the United States. Following the approval of Technegas by the United States Food and Drug Administration (USFDA) in September, this agreement signifies a major milestone for…
Radiopharmaceutical systems manufacturer Cyclopharm is expanding its manufacturing and storage capacity at Kingsgrove in Sydney to meet US demand, following approval by the USFDA for sale of the system in the big Uited States market. The Sydney company told investors it was preparing to air freight the first 20 Technegas systems to the USA, with…
The US Food and Drug Administration has approved Cyclopharm’s lung imagining technology Technegas, opening up a US$180 million market that has the potential to quadruple the size of Cyclopharm’s existing Pulmonary Embolism (PE) market. Technegas is an ultra-fine dispersion of the radiopharmaceutical Technetium-99m within a gas used in diagnostic functional lung imaging in 64 countries…
